PF-07868489
Sponsors
Pfizer Inc., Pfizer
Conditions
Pulmonary Arterial HypertensionPulmonary Hypertension
Phase 1
A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension
CompletedNCT06137742
Start: 2023-11-17End: 2026-07-31Updated: 2026-08-21
C5001001 - A Phase 1/2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of PF-07868489 in Healthy Adult Participants And, Additionally, Clinical Activity of Repeat Doses in Participants With Pulmonary Arterial Hypertension
Active, not recruitingCTIS2024-514064-17-00
Start: 2025-05-23Target: 32Updated: 2025-07-28
Phase 2
A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489
Active, not recruitingNCT07073820
Start: 2025-11-10End: 2028-08-24Updated: 2026-08-25
C5001004 - A Phase 2, Open-Label Extension Study to Investigate the Safety and Efficacy of PF-07868489 Administered to Adult Participants With Pulmonary Arterial Hypertension
RecruitingCTIS2025-521155-23-00
Start: 2025-12-19Target: 10Updated: 2025-12-22